4FRONT-1 Phase 3 expected data readout accelerated from H2 2027 to H1 2027 4FRONT-2 Phase 3 trial initiated ahead of schedule Streamlined late-stage clinical and pre-commercial organization aligns ...
SE stock is rated Hold due to valuation constraints and pipeline setbacks, despite strong commercial execution with VYVGART. Click here for more on ARGX.
Mike Exton, Chief Executive Officer, highlighted a pivotal exclusive license agreement with Novo Nordisk for LX9851, stating "this agreement grants Novo an exclusive worldwide license to develop, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback